Search

Search Results

• THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE

  Lucrezia Laterza, Gianenrico Rizzatti, Eleonora Gaetani, Patrizia Chiusolo, Antonio Gasbarrini

  e2016025

  2016-05-01

  https://doi.org/10.4084/mjhid.2016.025

  6150

  PDF: 2025

  HTML: 13963

  Untitled: 183

  figure: 159

• CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.

  Irene Motta, Valentina Ghiaccio, Andrea Cosentino, Laura Breda

  e2019067

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.067

  2758

  PDF: 1775

  HTML: 724

• ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS

  Lourdes Vazquez

  e2016040

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.040

  4175

  PDF: 1330

  HTML: 2022

• HAS HEMATOPOIETIC STEM CELL TRANSPLANTATION A ROLE IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA? Acute Promyelocytic Leukemia and Hematopoietic Stem Cell Transplantation

  Anna Maria Testi

  e2022038

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.038

  1029

  PDF: 703

  HTML: 183

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1337

  PDF: 628

  HTML: 1362

  cover letter: 187

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1588

  PDF: 1590

  HTML: 730

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  805

  PDF: 279

  Html: 58

• Acquired von Willebrand Syndrome associated to secondary IgM MGUS emerging after Autologous Stem Cell Transplantation for AL Amyloidosis

  Victor H Jimenez-Zepeda, Hina Qamar, Adrienne Lee, Karen Valentine, Leslie Skeith

  e2017034

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.034

  2576

  PDF: 1000

  HTML: 1149

• Successful treatment of gastric relapse in multiple myeloma with bortezomib after autologous hematopoietic stem cell transplantation (autoHSCT)

  Serdar Sivgin

  e2013006

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.006

  1090

  PDF: 586

  HTML: 3217

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3153

  PDF: 1562

  HTML: 1478

• Extending Long Term Follow-up of Patient With Acute Myeloid Leukemia after Autologous Stem Cell Transplantation: disclosing late mortality and causes of death.

  Federica Sorà, Patrizia Chiusolo, luca laurenti, idanna innocenti, francesco autore, andrea corbingi, andrea corbingi, sabrina giammarco, elisabetta metafuni, andrea bacigalupo, simona sica

  e2020030

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.030

  1323

  PDF: 581

  HTML: 183

• POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE

  Daniela Capello, Gianluca Gaidano

  e2009018

  https://doi.org/10.4084/mjhid.2009.018

  1189

  PDF: 449

  HTML: 18539

  Figure 1: 151

  Figure 2: 132

  Figure 3: 152

  Figure 4: 185

  Figure 5: 153

• PROPHYLACTIC ADMINISTRATION OF DOXYCYCLINE REDUCES CENTRAL VENOUS CATHETER INFECTIONS IN PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed Kharfan-Dabaja, Mohamed Baydoun, Zaher Otrock, Samar Okaily, Rita Nehme, Racha Abu-Chahine, Ali Hamdan, Samar Noureddine, Souha Kanj, Zeina Kanafani, Ali Bazarbachi

  e2013015

  2013-02-16

  https://doi.org/10.4084/mjhid.2013.015

  1450

  PDF: 825

  HTML: 1369

• IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Alana Kennedy-Nasser, Catherine Bollard, Helen Heslop

  e2009010

  2009-11-13

  https://doi.org/10.4084/mjhid.2009.010

  1077

  PDF: 578

  HTML: 6780

• ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed L. Sorror, Rainer F. Storb

  e2010015

  2010-06-08

  https://doi.org/10.4084/mjhid.2010.015

  939

  PDF: 602

  HTML: 2198

• CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA

  Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Luana Fianchi

  e2009030

  https://doi.org/10.4084/mjhid.2009.030

  1221

  PDF: 586

  HTML: 3051

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1366

  PDF: 474

  HTML: 167

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5340

  PDF: 2259

  HTML: 1306

• TREATMENT OF ADOLESCENT AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Josep-Maria Ribera, Jordi Ribera, Eulàlia Genescà

  e2014052

  2014-07-02

  https://doi.org/10.4084/mjhid.2014.052

  2515

  PDF: 1267

  HTML: 5884

• INFLUENZA AND PNEUMOCOCCAL VACCINATION IN HEMATOLOGICAL MALIGNANCIES: A SYSTEMATIC REVIEW OF EFFICACY, EFFECTIVENESS AND SAFETY

  Giuseppe La Torre

  e2016044

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.044

  4561

  PDF: 1405

  HTML: 3128

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3600

  PDF: 1009

  HTML: 1778

• DAYS ALIVE OUTSIDE HOSPITAL AND RE-ADMISSIONS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTS FROM IDENTICAL SIBLINGS, UNRELATED DONORS OR HAPLOIDENTICAL DONORS “.

  Federica Sorà, patrizia chiusolo, luca laurenti, idanna innocenti, francesco autore, sabrina giammarco, elisabetta metafuni, eleonora alma, alessia di giovanni, simona sica, andrea bacigalupo

  e2020055

  2020-08-29

  https://doi.org/10.4084/mjhid.2020.055

  1083

  PDF: 644

  HTML: 274

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2056

  PDF: 1509

  HTML: 247

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  1938

  PDF: 770

  HTML: 194

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1458

  PDF: 755

  HTML: 125

• OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia

  Erika Borlenghi, Tatiana Zollner, Giuseppe Rossi, Chiara Pagani, Michele Malagola, Alessandra Sottini, Diego Bertoli, Mariella Tonelli, Marco Chiarini, Chiara Cattaneo, Rossella Leopaldo, Angela Passi, Lorenzo Masina, Francesca Federico, Carlotta Giupponi, Alessandra Tucci

  e2024080

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.080

  1223

  PDF: 523

  Suppl. Files: 322

  HTML: 127

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4043

  PDF: 1413

  HTML: 569

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3416

  PDF: 2323

  HTML: 1401

• THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

  Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori

  e2012022

  2012-04-06

  https://doi.org/10.4084/mjhid.2012.022

  2102

  PDF: 837

  HTML: 1899

• GENE THERAPY IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Laura Breda, Roberto Gambari, Stefano Rivella

  e2009008

  2009-11-16

  1213

  PDF: 409

  HTML: 2865

• Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

  Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain

  e2010005

  2010-04-20

  https://doi.org/10.4084/mjhid.2010.005

  1049

  PDF: 546

  HTML: 1123

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1638

  PDF: 785

  HTML: 137

• POOR HEMOPOIETIC STEM CELL MOBILIZERS IN MULTIPLE MYELOMA : A SINGLE INSTITUTION EXPERIENCE

  Guillermo Jose Ruiz-Delgado, Avril Lopez-Otero, Ana Hernandez-Arizpe, Aura Ramirez-Medina, Guillermo Jose Ruiz-Argüelles

  e2010016

  2010-06-19

  https://doi.org/10.4084/mjhid.2010.016

  1126

  PDF: 705

  HTML: 567

• Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review

  Susmitha Apuri, Kristin Carlin, Edward Bass, Phuong Thuy Nguyen, John Norman Greene

  e2014014

  2014-02-18

  https://doi.org/10.4084/mjhid.2014.014

  3451

  PDF: 1437

  HTML: 4263

  CoverLetter: 167

  Figure1: 173

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2385

  PDF: 753

  HTML: 1718

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3522

  PDF: 1357

  HTML: 166

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2043

  PDF: 1916

  HTML: 137

• CLINICAL USEFULNESS OF BROCHOALVEOLAR LAVAGE IN THE MANAGEMENT OF PULMONARY INFILTRATES IN ADULTS WITH HAEMATOLOGICAL MALIGNANCIES AND STEM CELL TRANSPLANTATION

  Laura Jorge, Diego Torres, Agustín Languasco, Pablo Rodriguez, Pablo Bonvehí, Elena Temporiti, Silvia Relloso, Cristina Videla, Fabián Herrera

  e2020025

  2020-05-01

  https://doi.org/10.4084/mjhid.2020.025

  8004

  PDF: 730

  HTML: 198

• DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY

  John Norman Greene, Abraham Tareq Yacoub, Dani Thomas, Carol Yuan, Frank Walsh, David Solomon, Skai Schwartz, Arthur Andrews

  e2015002

  2014-12-19

  https://doi.org/10.4084/mjhid.2015.002

  1891

  PDF: 782

  HTML: 2187

  Table 1: 155

  Table 2: 170

  Table 3: 166

  Table 4: 171

  Table 5: 167

  Tble 6: 161

  Cover Letter: 182

  Greene Tab.7: 168

• LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B

  Eva Eliassen, Gerhard R Krueger, Mario Luppi, Dharam Ablashi

  e2018035

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.035

  3638

  PDF: 1404

  HTML: 455

  Figures . Eliassian: 198

• THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.

  Ugo Testa, Giuseppe Leone, Prof. M.D. Cappellini

  e2024068

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.068

  1960

  PDF: 1154

  Html: 254

• FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, Victoria Potter

  e2023041

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.041

  1413

  PDF: 669

  HTML: 198

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1420

  PDF: 1237

  HTML: 103

• MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

  Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan

  e2015001

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.001

  2176

  PDF: 1285

  HTML: 17047

  Bassan Fig.1: 133

  Bassan Fig.2: 129

  Bassan Fig.4: 124

  Fig.3: 161

• ACUTE PROMYELOCYTIC LEUKEMIA: AN EXPERIENCE ON 95 GREEK PATIENTS TREATED IN THE ALL-TRANS-RETINOIC ACID ERA

  Maria Pagoni, Maria Garofalaki, Fotios Panitsas, Kalliopi Manola, Katerina Psarra, Panagiotis Economopoulos

  e2011053

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.053

  2742

  PDF: 831

  HTML: 3434

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1915

  PDF: 1063

  HTML: 166

• NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?

  Alessandro Corso, Silvia Mangiacavalli

  e2017053

  2017-08-18

  https://doi.org/10.4084/mjhid.2017.053

  3115

  PDF: 1676

  HTML: 1066

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3289

  PDF: 1239

  HTML: 2187

  Fi.1 Gritti.Rambaldi: 181

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1014

  PDF: 675

  HTML: 598

• Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients

  Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini, Beatrice Casadei, Francesca Bonifazi, Pier Luigi Zinzani

  e2024004

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.004

  1340

  PDF: 1337

  HTML: 172